Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 dose-ranging study in moderate to severe chronic plaque psoriasis
2009-016807-42Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in psoriasis and plaque psoriasis (5 arms), sponsored by Novartis. Primary endpoint: PASI 75 achievement at week 12. Started Jan 2010; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2009-016807-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016807-42.